Long‑term treatment response in myelodysplastic syndrome 5q minus after discontinuation of lenalidomide – a case report

06/2020

MUDr. Petra Bělohlávková, Ph.D.

IV. interní hematologická klinika LF UK a FN Hradec Králové

SUMMARY

MDS 5q minus syndrome belongs to the category of low-risk MDS with a good prognosis. Lenalidomide treatment can effectively lead to transfusion independence and cytogenetic remission with improved the overall survival. We present a case of a patient in whom long-term remission of the disease lasts 5,5 years after discontinuation of treatment by lenalidomide.

Key words

del(5q), myelodysplastic syndromes, lenalidomide